Oculis (NASDAQ:OCS) Rating Reiterated by HC Wainwright

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $28.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 138.10% from the stock’s previous close.

OCS has been the subject of several other research reports. Robert W. Baird decreased their target price on Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a research note on Tuesday, March 19th. Wedbush restated an “outperform” rating and set a $29.00 target price on shares of Oculis in a research note on Wednesday, March 6th. Finally, Chardan Capital restated a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis presently has a consensus rating of “Buy” and an average price target of $30.17.

Oculis Stock Performance

OCS opened at $11.76 on Thursday. The company has a market cap of $476.28 million, a PE ratio of -6.57 and a beta of 0.53. The stock has a 50-day moving average of $11.94 and a 200-day moving average of $11.60. Oculis has a 52-week low of $9.05 and a 52-week high of $14.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.71 and a current ratio of 4.71.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.03). The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 52.72% and a negative net margin of 6,712.02%. As a group, equities research analysts forecast that Oculis will post -1.84 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Hedge funds have recently modified their holdings of the company. Wolverine Asset Management LLC acquired a new stake in Oculis during the 3rd quarter valued at $77,000. Searle & CO. bought a new position in Oculis during the fourth quarter worth about $112,000. Compagnie Lombard Odier SCmA raised its stake in shares of Oculis by 47.3% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares during the period. Finally, abrdn plc acquired a new stake in shares of Oculis in the 4th quarter valued at about $15,980,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.